Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients wih acute coronary syndromes scheduled for coronary intervention

Thrombosis and Haemostasis

Volumn 95, Issue 6, 2006, Pages 997-1002

  Siotia, Anjan ^a   Buckland, Robert ^a   Judge, Heather M ^a   Sastry, Padmini ^a   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Micro aggregation; Platelets; Tirofiban; Whole blood single platelet count

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; AUTOANALYZER; CELL ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MONITORING; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; SYNDROME; TYROSINE;

EID: 33745292588     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-08-0544     Document Type: Article

References (24)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
2. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/ IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-8.
3. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000; 101: 751-7.
4. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
5. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibafide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
6. Storey RF, May JA, Wilcox RG, et al. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost 1999; 82: 1307-11.
7. Smith JW, Steinhubl SR, Lincoff AM, et al. The rapid platelet function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5.
8. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
10. The EPISTENT Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-27.
11. Neumann FJ, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37: 1323-8.
12. Topol E, Moliterno D, Herrmann H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularisation. N Engl J Med 2001; 344: 1888-94.
13. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-24.
14. Danzi GB, Capuano C, Sesana M, et al. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Res Opin 2003; 19: 28-33.
15. Storey RF, Wilcox RG, Hepinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation 1998; 98: 1616-21.
16. Storey RF, Hepinstall S. Laboratory investigation of platelet function. Clin Lab Haematol 1999; 21: 317-9.
17. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of Antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
18. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004; 80: 155-64.
19. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349: 1422-8.
20. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94.
21. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 2037-44.
22. VerifyNOW™ IIb/IIIa Package Insert, Accumetrics. Available at http:// www.accumetrics.com/products/pdfs/14040.R.pdf.
23. Michelson AD, Bernard MR, Krueger LA, et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21: 259-70.
24. Peter K, Kohler B, Straub A, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase abciximab, and ticlopidine. Circulation 2000; 102: 1490.